All Stories

  1. Differentiating Upper Tract Urothelial Carcinoma with Synchronous or Metachronous Bladder Cancer
  2. CDKN2A homozygous deletions and TSC2 somatic mutations in metastatic pancreatic neuroendocrine tumors
  3. Genetic Background Dictates the Dichotomous Effects of Bisphenol A on Thyroid Cell Viability, Proliferation, and Migration
  4. Patient-derived tumoroids recapitulate the morphologic and molecular features of pediatric brain tumors
  5. Unravelling the Tumourigenesis Mechanisms of Oncocytic Cell Tumours: Discoveries from a Comparative Omics Study
  6. DICER1 and DGCR8 in Thyroid Tumorigenesis: miRNA Biogenesis and Histopathologic Diversity
  7. The Usefulness of Combined Digital Dermatoscopy and Ultrasound with Colour Doppler in the Diagnosis of Skin Lesions
  8. Exploring MAPK and mTOR Pathways in Feline Thyroid Tumors
  9. Challenges of the 5th Edition of the WHO Classification of Thyroid Tumours
  10. The hypothalamus-pituitary-thyroid axis is disrupted by exposure to a mix of tributyltin and bisphenol S
  11. Emerging Approaches in Glioblastoma Treatment: Modulating the Extracellular Matrix Through Nanotechnology
  12. Insights in biomarkers complexity and routine clinical practice for the diagnosis of thyroid nodules and cancer
  13. Nanostructured lipid carriers for enhanced batimastat delivery across the blood–brain barrier: an in vitro study for glioblastoma treatment
  14. TERTmonitor Efficacy and Performance in Detecting Mutations by Droplet Digital PCR
  15. Biomarker Profiling of Upper Tract Urothelial Carcinoma Only and with Synchronous or Metachronous Bladder Cancer
  16. Exploring the genetic links between voltage-gated potassium channels and familial non-medullary thyroid carcinoma: a family study
  17. Genomic profiling of lymph node and distant metastases from papillary and poorly differentiated thyroid carcinomas
  18. The relationship between the gut microbiota and thyroid disorders
  19. MODL-08. PATIENT-DERIVED ORGANOIDS RECAPITULATE THE MOLECULAR LANDSCAPE OF PEDIATRIC BRAIN TUMORS
  20. Unraveling the Significance of DGCR8 and miRNAs in Thyroid Carcinoma
  21. Cyto-Histological Profile of MicroRNAs as Diagnostic Biomarkers in Differentiated Thyroid Carcinomas
  22. Cyto-Histological Profile of microRNAs as Diagnostic Biomarkers in Differenciated Thyroid Carcinomas
  23. Urine-Based Biomarker Test Uromonitor® in the Detection and Disease Monitoring of Non-Muscle-Invasive Bladder Cancer—A Systematic Review and Meta-Analysis of Diagnostic Test Performance
  24. The Role of 5-Hydroxymethylcytosine as a Potential Epigenetic Biomarker in a Large Series of Thyroid Neoplasms
  25. Comparative Cyto-Histological Genetic Profile in a Series of Differentiated Thyroid Carcinomas
  26. Investigating USP42 Mutation as Underlying Cause of Familial Non-Medullary Thyroid Carcinoma
  27. Pyriproxyfen, villain or good guy? A brief review
  28. Comparative Cyto-histological Genetic Profile in a Series of Differentiated Thyroid Carcinomas
  29. Genomic profiling of primary and metastatic thyroid cancers
  30. Subcentimetric Papillary Thyroid Carcinoma: Does the Diagnosis Kind Impact Prognosis?
  31. Environmental Endocrinology: Parabens Hazardous Effects on Hypothalamic–Pituitary–Thyroid Axis
  32. Subcentimetric papillary thyroid carcinoma with extensive lymph node and brain metastasis: case report and review of literature
  33. TERTmonitor—qPCR Detection of TERTp Mutations in Glioma
  34. Environmental Endocrinology: Parabens Hazardous Effects on HPT Axis
  35. Significance of Furin Expression in Thyroid Neoplastic Transformation
  36. Personalized Medicine in Medullary Thyroid Carcinoma: A Broad Review of Emerging Treatments
  37. Using a Dual CRISPR/Cas9 Approach to Gain Insight into the Role of LRP1B in Glioblastoma
  38. 2023 European Thyroid Association Clinical Practice Guidelines for thyroid nodule management
  39. Generation of an Obese Diabetic Mouse Model upon Conditional Atrx Disruption
  40. Abstract
  41. High VEGFA Expression Is Associated with Improved Progression-Free Survival after Bevacizumab Treatment in Recurrent Glioblastoma
  42. Survey on selenium clinical supplementation in autoimmune thyroid disease
  43. Assessing the Antitumor Potential of Variants of the Extracellular Carbohydrate Polymer from Synechocystis ΔsigF Mutant
  44. Spotlight on hTERT Complex Regulation in Cutaneous T-Cell Lymphomas
  45. Endocrine-disrupting chemicals and endocrine neoplasia: A forty-year systematic review
  46. Yoga for COVID-19: An ancient practice for a new condition – A literature review
  47. Non-invasive follicular thyroid neoplasm with papillary-like nuclear feature: clinical, pathological, and molecular update 5 years after the nomenclature revision
  48. Prognostic Value of Bladder Involvement in the Outcome of Upper Tract Urothelial Carcinoma
  49. Position paper from the Endocrine Task Force of the European Organisation for Research and Treatment of Cancer (EORTC) on the management and shared decision making in patients with low-risk micro papillary thyroid carcinoma
  50. An update on genetically engineered mouse models of pancreatic neuroendocrine neoplasms
  51. DGCR8 Microprocessor Subunit Mutation and Expression Deregulation in Thyroid Lesions
  52. Case Report: Composite pheochromocytoma with ganglioneuroma component: A report of three cases
  53. HuRthle cell tumors vs oncocytic variants of the follicular cell derived thyroid tumours: a comprehensive analysis based in transcriptome, proteome and cnv profiling
  54. Tackling Thyroid Cancer in Europe—The Challenges and Opportunities
  55. Characterisation of an Atrx Conditional Knockout Mouse Model: Atrx Loss Causes Endocrine Dysfunction Rather Than Pancreatic Neuroendocrine Tumour
  56. Detection of SARS-CoV-2 infection in thyroid follicular cells from a COVID-19 autopsy series
  57. Environmentally relevant dose of the endocrine disruptor tributyltin disturbs redox balance in female thyroid gland
  58. Aggressive nonfunctioning pituitary neuroendocrine tumors
  59. Connexin Expression in Pituitary Adenomas and the Effects of Overexpression of Connexin 43 in Pituitary Tumor Cell Lines
  60. Subacute and low-dose tributyltin exposure disturbs the mammalian hypothalamus-pituitary-thyroid axis in a sex-dependent manner
  61. Post-COVID-19 Condition: Where Are We Now?
  62. The ringworm campaign in Portugal, 1940–1970
  63. Performance of the Bethesda System for Reporting Thyroid Cytology in Multi-Institutional Large Cohort of Pediatric Thyroid Nodules: A Detailed Analysis
  64. The Multifaceted Profile of Thyroid Disease in the Background of DICER1 Germline and Somatic Mutations: Then, Now and Future Perspectives
  65. Predictive Biomarkers in Melanoma: Detection of BRAF Mutation Using Dermoscopy
  66. <b><i>TERT</i></b> Promoter Mutational Status in the Management of Cutaneous Melanoma: Comparison with Sentinel Lymph Node Biopsy
  67. Ubiquitin-Specific Proteases: Players in Cancer Cellular Processes
  68. LRP1B: A Giant Lost in Cancer Translation
  69. DGCR8 microprocessor defect and deregulation of its expression in thyroid cancer
  70. Indeterminate thyroid cytology: detecting malignancy using analysis of nuclear images
  71. Epigenomics in Hurthle Cell Neoplasms: Filling in the Gaps Towards Clinical Application
  72. TERTp mutations and p53 expression in head and neck cutaneous basal cell carcinomas with different aggressive features
  73. Combinatorial Therapies to Overcome BRAF/MEK Inhibitors Resistance in Melanoma Cells: An in vitro Study
  74. Genetic Determinants for Prediction of Outcome of Patients with Papillary Thyroid Carcinoma
  75. Integrated Metabolomics and Transcriptomics Analysis of Monolayer and Neurospheres from Established Glioblastoma Cell Lines
  76. The role of c-Met and VEGFR2 in glioblastoma resistance to bevacizumab
  77. Molecular Pathology of Non-familial Follicular Epithelial–Derived Thyroid Cancer in Adults: From RAS/BRAF-like Tumor Designations to Molecular Risk Stratification
  78. Correlation of molecular data with histopathological and clinical features in a series of 66 patients with medullary thyroid carcinoma
  79. LRP1B Expression as a Putative Predictor of Response to Pegylated Liposomal Doxorubicin Treatment in Ovarian Cancer
  80. Osteopontin-a enhances cytoskeleton remodeling and activates intermediate epithelial mesenchymal properties in c643 thryoid cancer cells
  81. Mohs Micrographic Surgery for Head and Neck Nonmelanoma Skin Cancer: An Approach for Ent Surgeons
  82. S616-p-DRP1 associates with locally invasive behavior of follicular cell-derived thyroid carcinoma
  83. Clinicopathological Features as Prognostic Predictors of Poor Outcome in Papillary Thyroid Carcinoma
  84. Molecular Aspects of Thyroid Calcification
  85. Metabolic modulation combined with mTOR pathway inhibition may overcame cutaneous melanoma resistance to MAPK inhibitors treatment
  86. Clinical Validation of a Urine Test (Uromonitor-V2®) for the Surveillance of Non-Muscle-Invasive Bladder Cancer Patients
  87. Follicular Lesions with Papillary Nuclear Characteristics: Differences in Chromatin Detected by Computerized Image Analysis
  88. Analyzing the Role of DICER1 Germline Variations in Papillary Thyroid Carcinoma
  89. Predictive Biomarkers and Patient Outcome in Platinum-Resistant (PLD-Treated) Ovarian Cancer
  90. Comprehensive Assessment of TERT mRNA Expression across a Large Cohort of Benign and Malignant Thyroid Tumours
  91. Prognostic Significance of RAS Mutations and P53 Expression in Cutaneous Squamous Cell Carcinomas
  92. Erratum to “Gastroenteropancreatic Neuroendocrine Neoplasia Characterization in Portugal: Results from the NETs Study Group of the Portuguese Society of Endocrinology, Diabetes and Metabolism”
  93. A 30-Year Long-Term Experience in Appendix Neuroendocrine Neoplasms—Granting a Positive Outcome
  94. Evaluation of the role of mitochondria in the non-targeted effects of ionizing radiation using cybrid cellular models
  95. Reliable blood cancer cells' telomere length evaluation by qPCR
  96. Head and neck cutaneous basal cell carcinoma: what should the otorhinolaryngology head and neck surgeon care about?
  97. Relevant dose of the environmental contaminant, tributyltin, promotes histomorphological changes in the thyroid gland of male rats
  98. TERT Promoter Mutation as a Potential Predictive Biomarker in BCG-Treated Bladder Cancer Patients
  99. Biomarkers for Bladder Cancer Diagnosis and Surveillance: A Comprehensive Review
  100. Cancer incidence after childhood irradiation for tinea capitis in a Portuguese cohort
  101. Abstracts of the 17th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease
  102. Validation of a Novel, Sensitive, and Specific Urine-Based Test for Recurrence Surveillance of Patients With Non-Muscle-Invasive Bladder Cancer in a Comprehensive Multicenter Study
  103. Variants of Papillary Thyroid Carcinoma: An Algorithmic Cytomorphology-Based Approach to Cytology Specimens
  104. Predicting Growing Stock Volume of Eucalyptus Plantations Using 3-D Point Clouds Derived from UAV Imagery and ALS Data
  105. Characterization and antitumor activity of the extracellular carbohydrate polymer from the cyanobacterium Synechocystis ΔsigF mutant
  106. Interaction of Genetic Variations inNFE2L2andSELENOSModulates the Risk of Hashimoto's Thyroiditis
  107. Gastroenteropancreatic Neuroendocrine Neoplasia Characterization in Portugal: Results from the NETs Study Group of the Portuguese Society of Endocrinology, Diabetes and Metabolism
  108. Differential Expression of HMGA1 and HMGA2 in pituitary neuroendocrine tumors
  109. Oncocytic thyroid neoplasms: from histology to molecular biology
  110. “The other side of the coin”: understanding noninvasive follicular tumor with papillary-like nuclear features in unifocal and multifocal settings
  111. TERT promoter mutations are associated with poor prognosis in cutaneous squamous cell carcinoma
  112. TERT promoter and FGFR3 mutations – a highly sensitive and non-invasive tool for bladder cancer recurrence detection
  113. Scalp basal cell carcinoma: A different entity?
  114. Tendências do carcinoma espinocelular cutâneo no Hospital de Gaia (2004-20013)
  115. Selenium and Selenoproteins in Immune Mediated Thyroid Disorders
  116. The environmental contaminant tributyltin leads to abnormalities in different levels of the hypothalamus-pituitary-thyroid axis in female rats
  117. OPNa Overexpression Is Associated with Matrix Calcification in Thyroid Cancer Cell Lines
  118. Uromonitor®as a novel sensitive and specific urine-based test for recurrence surveillance of patients with non-muscle invasive bladder cancer
  119. The genetics of cutaneous squamous cell carcinogenesis
  120. Liposomal therapies in oncology: does one size fit all?
  121. Editorial on “The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma”
  122. Follicular thyroid lesions: is there a discriminatory potential in the computerized nuclear analysis?
  123. Unraveling molecular targets of bisphenol A and S in the thyroid gland
  124. Abstract 180: OPNa variant expression is associated with matrix mineralization in thyroid cancer cell lines
  125. TERTp mutation is associated with a shorter progression free survival in patients with aggressive histology subtypes of follicular-cell derived thyroid carcinoma
  126. Melanoma treatment in review
  127. Cribriform-morular variant of thyroid carcinoma: a neoplasm with distinctive phenotype associated with the activation of the WNT/β-catenin pathway
  128. mTOR Pathway in Papillary Thyroid Carcinoma: Different Contributions of mTORC1 and mTORC2 Complexes for Tumor Behavior and SLC5A5 mRNA Expression
  129. Age-Associated Mortality Risk in Papillary Thyroid Cancer: Does BRAF Make a Real Difference?
  130. Telomere Maintenance Mechanisms in Cancer
  131. Tributyltin and Zebrafish: Swimming in Dangerous Water
  132. Genomic and transcriptomic characterization of the mitochondrial-rich oncocytic phenotype on a thyroid carcinoma background
  133. Is Low-Dose Radiation Exposure a Risk Factor for Atherosclerotic Disease?
  134. Multinodular Goiter Progression Toward Malignancy in a Case of DICER1 Syndrome
  135. Dynamin-Related Protein 1 at the Crossroads of Cancer
  136. CRABP1, C1QL1 and LCN2 are biomarkers of differentiated thyroid carcinoma, and predict extrathyroidal extension
  137. NIS expression in thyroid tumors, relation with prognosis clinicopathological and molecular features
  138. Frontiers in endocrine disruption: Impacts of organotin on the hypothalamus-pituitary-thyroid axis
  139. Etiopathogenesis of oncocytomas
  140. Inhibitory Effects of Antagonists of Growth Hormone-Releasing Hormone (GHRH) in Thyroid Cancer
  141. Calcitonin receptor expression in medullary thyroid carcinoma
  142. Introduction
  143. Other Rare Tumours and Tumour-Like Lesions
  144. Rare Familial Tumours
  145. Rare Follicular Tumours
  146. Rare Papillary Thyroid Carcinomas
  147. Small Cell Tumours
  148. Therapeutic Options
  149. SDHD promoter mutations are rare events in cutaneous melanomas but SDHD protein expression is downregulated in advanced cutaneous melanoma
  150. Hobnail Variant of Papillary Thyroid Carcinoma
  151. Telomerase and N-Cadherin in Adrenocortical Tumors
  152. The Genetics of Papillary Microcarcinomas of the Thyroid: Diagnostic and Prognostic Implications
  153. Molecular landscape of metastatic thyroid cancer
  154. The role of ablative treatment in differentiated thyroid cancer management
  155. TERTbiology and function in cancer: beyond immortalisation
  156. Molecular study on some antibiotic resistant genes in Salmonella spp. isolates
  157. The biology and the genetics of Hürthle cell tumors of the thyroid
  158. In vitro transforming potential, intracellular signaling properties and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu and Arg886Trp
  159. pmTOR is a marker of aggressiveness in papillary thyroid carcinomas
  160. TERTpromoter mutations: a genetic signature of benign and malignant thyroid tumours occurring in the context of tinea capitis irradiation
  161. IL6-174 G>C Polymorphism (rs1800795) Association with Late Effects of Low Dose Radiation Exposure in the Portuguese Tinea Capitis Cohort
  162. The Role of ATRX in the Alternative Lengthening of Telomeres (ALT) Phenotype
  163. Telomerase Activation in Hematological Malignancies
  164. Erratum: Chromosomal, epigenetic and microRNA-mediated inactivation of LRP1B, a modulator of the extracellular environment of thyroid cancer cells
  165. TERT promoter mutations in pancreatic endocrine tumours are rare and mainly found in tumours from patients with hereditary syndromes
  166. Osteopontin-a splice variant is overexpressed in papillary thyroid carcinoma and modulates invasive behavior
  167. Corrigendum to “How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer”
  168. Molecular profiling, including TERT promoter mutations, of acral lentiginous melanomas
  169. The prognostic impact of TERT promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism
  170. Telomerase promoter mutations in cancer: beyond immortalization?
  171. TERT promoter mutations in pancreatic endocrine tumours are frequent in tumours from patients with hereditary syndromes
  172. Osteopontin expression is correlated with differentiation and good prognosis in medullary thyroid carcinoma
  173. TERT Promoter Mutations in Soft Tissue Sarcomas
  174. Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants
  175. Thyroid and Parathyroid Glands
  176. Obesity Is Associated With Low NAD+/SIRT Pathway Expression in Adipose Tissue of BMI-Discordant Monozygotic Twins
  177. Molecular Markers Involved in Tumorigenesis of Thyroid Carcinoma: Focus on Aggressive Histotypes
  178. Hotspot TERT promoter mutations are rare events in testicular germ cell tumors
  179. RAF-1 promotes survival of thyroid cancer cells harboring RET/PTC1 rearrangement independently of ERK activation
  180. ENDOCRINE TUMOURS: Genetic predictors of thyroid cancer outcome
  181. ESP Abstracts 2015
  182. Overexpression of pyruvate dehydrogenase kinase supports dichloroacetate as a candidate for cutaneous melanoma therapy
  183. Mitochondrial Dynamics Protein Drp1 Is Overexpressed in Oncocytic Thyroid Tumors and Regulates Cancer Cell Migration
  184. RE: TERT Promoter Mutation Status as an Independent Prognostic Factor in Cutaneous Melanoma
  185. Coexistence of TERT Promoter and BRAF Mutations in Papillary Thyroid Carcinoma: Added Value in Patient Prognosis?
  186. Hashimoto’s Thyroiditis in Adolescents
  187. Poorly differentiated and undifferentiated thyroid carcinomas
  188. OXPHOS dysfunction regulates integrin- 1 modifications and enhances cell motility and migration
  189. mTOR activation in medullary thyroid carcinoma with RAS mutation
  190. Low frequency of TERT promoter mutations in gastrointestinal stromal tumors (GISTs)
  191. Differentiated thyroid cancer in patients with resistance to thyroid hormone syndrome. A novel case and a review of the literature
  192. Thyroid and parathyroid tumours in patients submitted to X-ray scalp epilation during the tinea capitis eradication campaign in the North of Portugal (1950–1963)
  193. Polymorphisms in the TNFA and IL6 Genes Represent Risk Factors for Autoimmune Thyroid Disease
  194. TERT Promoter Mutations in Skin Cancer: The Effects of Sun Exposure and X-Irradiation
  195. Telomerase promoter mutations in cancer: an emerging molecular biomarker?
  196. Increased lymphangiogenesis in Riedel thyroiditis (Immunoglobulin G4-related thyroid disease)
  197. TERT Promoter Mutations Are a Major Indicator of Poor Outcome in Differentiated Thyroid Carcinomas
  198. A Polymorphism in the Promoter Region of the Selenoprotein S Gene (SEPS1) Contributes to Hashimoto's Thyroiditis Susceptibility
  199. C-Cell-Derived Calcitonin-Free Neuroendocrine Carcinoma of the Thyroid
  200. Prognostic biomarkers in thyroid cancer
  201. Papillary Thyroid Microcarcinoma
  202. Mitochondrial D310 D-Loop instability and histological subtypes in radiation-induced cutaneous basal cell carcinomas
  203. Primary Squamous Cell Carcinoma of the Thyroid Diagnosed as Anaplastic Carcinoma: Failure in Fine-Needle Aspiration Cytology?
  204. Stimulated Thyroglobulin at Recombinant Human TSH-Aided Ablation Predicts Disease-free Status One Year Later
  205. Abstract C118: TERT promoter mutations in human gliomas.
  206. A founder SDHB mutation in Portuguese paraganglioma patients
  207. Genetic alterations in thyroid tumors from patients irradiated in childhood for tinea capitis treatment
  208. Nrf2 Is Commonly Activated in Papillary Thyroid Carcinoma, and It Controls Antioxidant Transcriptional Responses and Viability of Cancer Cells
  209. Frequency of TERT promoter mutations in human cancers
  210. GNAQ and BRAF mutations show differential activation of the mTOR pathway in human transformed cells
  211. Etiopathogenic factors of thyroid cancer
  212. Radiotherapy: radioiodine and external beam irradiation treatment of differentiated thyroid carcinomas
  213. Cribriform-Morular Variant of Papillary Thyroid Carcinoma Displaying Poorly Differentiated Features
  214. CDX2 Expression in Some Variants of Papillary Thyroid Carcinoma
  215. MEN1 intragenic deletions may represent the most prevalent somatic event in sporadic primary hyperparathyroidism
  216. AZD1480 Blocks Growth and Tumorigenesis of RET- Activated Thyroid Cancer Cell Lines
  217. Survey of 548 oncogenic fusion transcripts in thyroid tumors supports the importance of the already established thyroid fusions genes
  218. Molecular alterations and expression of succinate dehydrogenase complex in wild-type KIT/PDGFRA/BRAF gastrointestinal stromal tumors
  219. STAT3 negatively regulates thyroid tumorigenesis
  220. RET/PTCrearrangement is prevalent in follicular Hürthle cell carcinomas
  221. mTOR Pathway Overactivation in BRAF Mutated Papillary Thyroid Carcinoma
  222. 1121 BRAF Mutations in Thyroid Carcinomas Following Childhood Scalp Irradiation
  223. Insights into melanoma: targeting the mTOR pathway for therapeutics
  224. TGF-beta/Smad pathway and BRAF mutation play different roles in circumscribed and infiltrative papillary thyroid carcinoma
  225. The biology and the genetics of Hurthle cell tumors of the thyroid
  226. Absence of theBRAFand theGRIM-19Mutations in Oncocytic (Hürthle Cell) Solid Cell Nests of the Thyroid
  227. Head and neck basal cell carcinoma prevalence in individuals submitted to childhood X-ray epilation for tinea capitis treatment
  228. The mTOR Signalling Pathway in Human Cancer
  229. Melanocytic Tumour in a Black Sheep never exposed to Ultraviolet Radiation
  230. A Clear Cell Renal Cell Carcinoma Inhibiting the Response to Intravitreal Antivascular Endothelial Growth Factor Therapy in Wet Age-Related Macular Disease
  231. Paraganglioma of seminal vesicle and chromophobe renal cell carcinoma: a case report and literature review
  232. A novel germline SDHB mutation in a gastrointestinal stromal tumor patient without bona fide features of the Carney–Stratakis dyad
  233. Genetic Alterations in Poorly Differentiated and Undifferentiated Thyroid Carcinomas
  234. Intratumoural lymph vessel density is related to presence of lymph node metastases and separates encapsulated from infiltrative papillary thyroid carcinoma
  235. Impact of EGFR Genetic Variants on Glioma Risk and Patient Outcome
  236. GRIM-19 function in cancer development
  237. Orthovanadate-induced cell death in RET/PTC1-harboring cancer cells involves the activation of caspases and altered signaling through PI3K/Akt/mTOR
  238. Synergistic growth inhibition of cancer cells harboring the RET/PTC1 oncogene by staurosporine and rotenone involves enhanced cell death
  239. Plenary Oral Free Paper Sessions
  240. The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases
  241. In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp
  242. Abstract 1075: STAT3 signaling in thyroid cancer
  243. Involvement of p53 in cell death following cell cycle arrest and mitotic catastrophe induced by rotenone
  244. Head and neck lesions in a cohort irradiated in childhood for tinea capitis treatment
  245. Thyroid hormone as a regulator of tumor induced angiogenesis
  246. Tumor-in-Tumor of the Thyroid With Basaloid Differentiation: A Lesion With a Solid Cell Nest Neoplastic Component?
  247. Molecular Alterations in Sporadic Primary Hyperparathyroidism
  248. Small papillary thyroid cancers—is BRAF of prognostic value?
  249. EBV interferes with the sensitivity of Burkitt lymphoma Akata cells to etoposide
  250. How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer
  251. mTOR pathway activation in cutaneous melanoma is associated with poorer prognosis characteristics
  252. Chromosomal, epigenetic and microRNA-mediated inactivation of LRP1B, a modulator of the extracellular environment of thyroid cancer cells
  253. Analysis of GNAQ mutations, proliferation and MAPK pathway activation in uveal melanomas
  254. Multicentre validation study of nucleic acids extraction from FFPE tissues
  255. 95 Associations between functional EGFR polymorphisms and glioma risk
  256. Hot Topics in Papillary Thyroid Carcinoma
  257. Molecular Pathology of Thyroid Tumors: Diagnostic and Prognostic Relevance
  258. Alopecia in women submitted to childhood X-ray epilation for tinea capitis treatment
  259. Review Article: The Familial Counterparts of Follicular Cell—Derived Thyroid Tumors
  260. Identification of a paired box gene 8-peroxisome proliferator-activated receptor gamma (PAX8-PPAR ) rearrangement mosaicism in a patient with an autonomous functioning follicular thyroid carcinoma bearing an activating mutation in the TSH receptor
  261. Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma
  262. Abstract 3138: Stat3 signaling in thyroid cancer
  263. An assessment of the clonality of the components of canine mixed mammary tumours by mitochondrial DNA analysis
  264. Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations
  265. A follicular variant of papillary thyroid carcinoma in struma ovarii. Case report with unique molecular alterations
  266. IsBRAFmutation screening useful for preoperative risk stratification in papillary thyroid cancer?
  267. BRAFV600Emutation in papillary thyroid carcinoma: a potential target for therapy?
  268. Germline variation of the melanocortin-1 receptor does not explain shared risk for melanoma and thyroid cancer
  269. Mitochondria and cancer
  270. How molecular pathology is changing and will change the therapeutics of patients with follicular cell-derived thyroid cancer
  271. Cribriform-Morular Variant of Papillary Thyroid Carcinoma
  272. Mitochondria and Oncocytomas
  273. Cyclic AMP Inhibits the Proliferation of Thyroid Carcinoma Cell Lines through Regulation of CDK4 Phosphorylation
  274. Acquisition ofBRAFgene mutations is not a requirement for nodal metastasis of papillary thyroid carcinoma
  275. Follicular thyroid carcinoma with an unusual glomeruloid pattern of growth
  276. Optimization of methods to assess mitochondrial DNA in archival paraffin-embedded tissues from mammary canine tumors
  277. Intragenic Mutations in Thyroid Cancer
  278. GRIM-19 in Health and Disease
  279. Mitochondria and Cancer
  280. BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAFV600E but not KRAS mutations
  281. Loss of heterozygosity at 19p13.2 and 2q21 in tumours from familial clusters of non-medullary thyroid carcinoma
  282. Molecular and Genotypic Characterization of Human Thyroid Follicular Cell Carcinoma–Derived Cell Lines
  283. Molecular genetics of papillary thyroid carcinoma: great expectations...
  284. A subset of colorectal carcinomas express c-KIT protein independently of BRAF and/or KRAS activation
  285. Thyroid hormone receptor   mutations in the 'hot-spot region' are rare events in thyroid carcinomas
  286. B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas
  287. The p75 neurotrophin receptor is widely expressed in conventional papillary thyroid carcinoma
  288. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto‐oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal
  289. Mutational Spectrum and Linkage Disequilibrium Patterns at the Ornithine Transcarbamylase Gene (OTC)
  290. H-RAS 81 polymorphism is significantly associated with aneuploidy in follicular tumors of the thyroid
  291. PAX8-PPARγ Rearrangement Is Frequently Detected in the Follicular Variant of Papillary Thyroid Carcinoma
  292. Diagnostic Criteria in Well-Differentiated Thyroid Carcinomas
  293. Reply to: Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas
  294. Mitochondrial D-Loop instability in thyroid tumours is not a marker of malignancy
  295. Molecular pathology of well-differentiated thyroid carcinomas
  296. A new BRAF gene mutation detected in a case of a solid variant of papillary thyroid carcinoma
  297. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients’ age but not with tumour aggressiveness
  298. A stem cell role for thyroid solid cell nests
  299. Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hürthle cell) tumours of the thyroid
  300. Cystic Tumor of the Atrioventricular Node of the Heart Appears to Be the Heart Equivalent of the Solid Cell Nests (Ultimobranchial Rests) of the Thyroid
  301. Cystic Tumor of the Atrioventricular Node of the Heart Appears to Be the Heart Equivalent of the Solid Cell Nests (Ultimobranchial Rests) of the Thyroid
  302. Hürthle (Oncocytic) Cell Tumors of Thyroid: Etiopathogenesis, Diagnosis and Clinical Significance
  303. Adenomas and follicular carcinomas of the thyroid display two major patterns of chromosomal changes
  304. Mutation analysis of B-RAF gene in human gliomas
  305. Mutated E-Cadherin: Genomic and Functional Characterization in Thyroid Cells from the KAT Family
  306. BRAFMutations Are Not a Major Event in Post-Chernobyl Childhood Thyroid Carcinomas
  307. BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas
  308. Telomerase expression and proliferative activity suggest a stem cell role for thyroid solid cell nests
  309. Core I gene is overexpressed in Hürthle and non-Hürthle cell microfollicular adenomas and follicular carcinomas of the thyroid
  310. BRAF mutations are associated with some histological types of papillary thyroid carcinoma
  311. Lewis Antigen Expression in Gastric Mucosa of Children: Relationship With Helicobacter pylori Infection
  312. Germline Succinate Dehydrogenase Subunit D Mutation Segregating with Familial Non-RET C Cell Hyperplasia
  313. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC
  314. E-cadherin loss rather than beta-catenin alterations is a common feature of poorly differentiated thyroid carcinomas
  315. Immunohistochemical study of heat shock proteins 27, 60 and 70 in the normal human adrenal and in adrenal tumors with suppressed ACTH production
  316. Re: Lohrer,H.D., Hieber,L. and Zitzelsberger,H. (2002) Differential mutation frequency in mitochondrial DNA from thyroid tumours. Carcinogenesis, 23, 1577-1582
  317. Letter to the editor
  318. Vascular Invasion in Thyroid and Gastric Carcinomas
  319. p63 Expression in Solid Cell Nests of the Thyroid: Further Evidence for a Stem Cell Origin
  320. Loss of Heterozygosity and Promoter Methylation, but not Mutation, May Underlie Loss of TFF1 in Gastric Carcinoma
  321. Mucoepidermoid carcinoma of the thyroid: a tumour histotype characterised by P-cadherin neoexpression and marked abnormalities of E-cadherin/catenins complex
  322. Mitochondrial DNA Somatic Mutations (Point Mutations and Large Deletions) and Mitochondrial DNA Variants in Human Thyroid Pathology
  323. Poorly Differentiated Carcinomas of the Thyroid Gland
  324. Specific haplotypes of the RET proto-oncogene are over-represented in patients with sporadic papillary thyroid carcinoma
  325. Letter to the editors
  326. P63 Expression in Papillary and Anaplastic Carcinomas of the Thyroid Gland: Lack of an Oncogenetic Role in Tumorigenesis and Progression
  327. Diffuse (or multinodular) follicular variant of papillary thyroid carcinoma: a clinicopathologic and immunohistochemical analysis of ten cases of an aggressive form of differentiated thyroid carcinoma
  328. Microsatellite instability, mitochondrial DNA large deletions, and mitochondrial DNA mutations in gastric carcinoma
  329. Abnormalities of the E-cadherin/catenin adhesion complex in classical papillary thyroid carcinoma and in its diffuse sclerosing variant
  330. E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma
  331. Fetal adenomas and minimally invasive follicular carcinomas of the thyroid frequently display a triploid or near triploid DNA pattern
  332. Mitochondrial DNA alteration in gastric cancer
  333. Extended structural variation of a pentanucleotide repeat in the GSTP1 gene: characterisation in a normal population and in thyroid and gastric tumours
  334. Clinicopathologic and prognostic significance of the expression of mucins, simple mucin antigens and histoblood group antigens in papillary thyroid carcinoma
  335. Papillary thyroid carcinoma overexpresses fully and underglycosylated mucins together with native and sialylated simple mucin antigens and histo-blood group antigens
  336. Comments on: Mutations in Mitochondrial Control Region DNA in Gastric Tumours of Japanese Patients, Tamura, et al. Eur J Cancer 1999, 35, 316–319
  337. E-cadherin gene mutations provide a genetic basis for the phenotypic divergence of mixed gastric carcinomas
  338. Sporadicret-rearranged papillary carcinoma of the thyroid: a subset of slow growing, less aggressive thyroid neoplasms?
  339. The Common Deletion of Mitochondrial DNA is Found in Goiters and Thyroid Tumors with and Without Oxyphil Cell Change
  340. Prognosefaktoren bei differenzierten Schilddrüsenkarzinomen
  341. Benign and malignant thyroid lesions show instability at microsatellite loci
  342. E-cadherin gene alterations are rare events in thyroid tumors
  343. Recent Advances in Cytometry, Cytogenetics and Molecular Genetics of Thyroid Tumours and Tumour-like Lesions
  344. Chromosome analysis of 73 thyroid neoplasms
  345. Correspondence
  346. Immunohistochemical detection of p53 in differentiated, poorly differentiated and undifferentiated carcinomas of the thyroid
  347. Expression of C‐erb B2 in tumours and tumour‐like lesions of the thyroid
  348. Thyroid nodular hyperplasia
  349. Cytogenetic findings in eleven gastric carcinomas
  350. Cytogenetic findings in 18 follicular thyroid adenomas
  351. Clonal cytogenetic abnormalities and telomeric associations in a fibroxanthoma of the stomach
  352. C-erbB-2 expression in primary gastric carcinomas and their metastases
  353. Loss of Y chromosome in gastric carcinoma
  354. Signet Ring Cell Carcinoma of the Stomach: A Morphometric, Ultrastructural, and DNA Cytometric Study